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Abstract
During severe acute respiratory syndrome coronavirus (CoV)-2- induced CoV disease (COVID)-19 pandemic 
cutaneous signs of the disease gained increasing interest for early diagnosis, to establish a prognosis and for 
differential diagnoses. The present review aims to summarize current knowledge on cutaneous findings in COVID-
19. The findings are classified and described clinically. The spectrum of cutaneous signs include acro-ischemic 
lesions, rash, chilblain-like eruptions, and androgenetic alopecia. Their significance is given, and treatment options 
are presented. This may allow the clinicians to support triage and optimal treatment for COVID-19 patients.
Key Bullets
•     The COVID-19 pandemic has affected patients world-wide. Despite the leading symptoms are in the respiratory, 
cardiovascular, hematologic, and neurologic systems, cutaneous manifestations are increasingly be observed.
•     Cutaneous findings in COVID-19 patients may have prognostic and therapeutic consequences. This review 
attempts to classify cutaneous symptoms, document the observed frequency of their occurrence, the 
significance for triage of COVID-19-patients, and the treatment of cutaneous manifestations.
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Introduction
The coronavirus (CoV) disease (COVID)-
19 pandemic originated in Wuhan, China, and is 
caused by a new beta-CoV, named severe acute 
respiratory syndrome-CoV (SARS-CoV)-2 [1]. The 
virus enters host cells with the support of its surface 
spike proteins. Angiotensin-converting enzyme 2 
(ACE2) has been identified as the entry receptor and 
employs the cellular serine protease TMPRSS2 for 
S protein priming [2]. Since ACE2 is regulated by 
androgens, this may contribute to the higher rate of 
males affected [3].
Infection can be from animals to humans and 
human-to-human. Among humans, the most common 
transmission is by respiratory droplets. The primary 
entry point is the respiratory system, although the 
virus can also infect the digestive, urinary, neurologic, 
and hematologic system. Other possible ways of 
transmission are fecal-oral and mother-to-child. 
Incubation time varies between 5 and 14 days, seldom 
longer [4].
Typical symptoms of infection by SARS-
CoV-2 are fever, fatigue, dry cough, dyspnea, 
with or without nasal congestion, runny nose or 
other upper respiratory symptoms, lymphopenia, 
thrombocytopenia, and leukopenia. Patients may 
present with atypical symptoms such as headache, 
vomiting, diarrhea, and hemoptysis or stay 
asymptomatic [5], [6].
Complications include the acute respiratory 
distress syndrome, acute heart injury, stroke, 
encephalopathy, and secondary infections [5], [7], [8]. 
Patients older than 60 years and/or comorbidities 
are at higher risk for complications, hospitalization, 
and mortality. The rate of patients to be treated at the 
intensive care unit (ICU) varies from nearly 30% in the 
initial Wuhan epidemic to around 12% on northern Italy 
and 7% in Germany [9], [10], [11].
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Distribution of SARS-CoV-2 in Human 
Tissues
Three autopsy cases from Chongqing, China, 
demonstrated by immunohistochemistry that alveolar 
epithelia and macrophages were partially positive for 
the 2019-nCoV antigen. Real-time -polymerase chain 
reaction (rT-PCR) analyses identified positive signals 
for 2019-nCoV nucleic acid [12]. In two autopsies from 
Cleveland/OH, USA, viral RNA was detected in lungs, 
bronchi, lymph nodes, and spleen using quantitative 
rT-PCR method on formalin-fixed paraffin-embedded 
tissue specimen [13]. Among 26 autopsy cases 
from Wuhan, China, immunostaining with SARS-
CoV nucleoprotein antibody was positive in renal 
tubules [14]. In 12 patients who died from COVID-19 in 
Hamburg/ Germany, SARS-CoV-2 RNA was detected 
in the lung at high concentrations. Viremia in 6 of 10 
and 5 of 12 patients demonstrated high viral RNA 
titers in the liver, kidney, or heart during autopsy [15]. 
In three autopsy cases from Zürich, Switzerland, 
presence of viral elements within endothelial cells 
and the induction of endotheliitis in several organs as 
a direct consequence of viral involvement have been 
documented [16].
The expression of ACE2 was demonstrated 
in human skin samples using single-cell RNA 
sequencing. It was significantly higher in keratinocytes 
than other cell types in skin, such as fibroblasts and 
melanocytes. Immunostainings for ACE2 were positive 
in epidermal basal layer, stratum spinosum and stratum 
granulosum [17]. SARS-CoV-2, on the contrary, has not 
been detected in skin [12].
By the support of neuronal network possible 
conceptual associations from unstructured text and 
triangulation with insights from single cell RNA-
sequencing (seq), bulk RNAseq and proteomics from 
diverse tissue types have been analyzed. It could be 
demonstrated that tongue keratinocytes, olfactory 
epithelial cells, airway club cells, and respiratory 
ciliated cells are potential reservoirs of the SARS-
CoV-2 receptor. The gut was identified as the putative 
hotspot of COVID-19, where a maturation correlated 
transcriptional signature is shared in small intestine 
enterocytes among CoV receptors (ACE2 and 
others) [18].
Epidemiology of Cutaneous Manifestation 
of COVID-19
The initial trials from Wuhan suggested a low 
prevalence of 0.2% of any cutaneous findings among 
symptomatic patients [19]. The prevalence of cutaneous 
manifestations in uncontrolled trials and reports varies 
extremely from zero (Tibetan highland) to almost 100% 
(Thailand) [20].
There is a need for better epidemiological data 
on the subject. One initiative to improve data collection 
and analysis comes from the American Academy of 
Dermatology [21].
Classification of COVID-19-related 
Cutaneous Manifestations
A nationwide Spanish study among 
dermatologists included 375 COVID-19 cases with 
cutaneous manifestations. Based on this large data set, 
the authors tried to classify the cutaneous findings into 
five categories [22]:
•  Asymmetrical distributed chilblain-like acral 
areas of erythema and/or edema with some 
vesicles or pustules (pseudo-chilblain) on 
digits hand and feet and heels
•  Vesicular monomorphic eruptions (varicella-like)
•  Urticarial lesions
•  Maculopapular rash
•  Acro-ischemic lesions (Livedo or necrosis).
We had like to add some more possible 
cutaneous findings:
1. Symmetrical flexural and intertriginous 
exanthema
2. Purpuric rash
3. Erythema multiforme-like rash and Kawasaki-
like disease/multisystemic inflammatory 
syndrome in children (MIS-C)
4. Others (Mottling, Sweet syndrome-like, 
pustular eruptions, and androgenetic alopecia 
[AGA]) (Table 1).
Table 1: Cutaneous signs of COVID-19, their frequency and 
significance
Cutaneous signs Frequency Remarks Significance
CE up to 19% Mostly children Mild or silent disease
Vesicular 
eruptions
9–15% Symptomatic adults Could be a sign of a viral 
coinfection
Urticarial lesions 1.4–19% Often with pyrexia In case of eosinophilia, the 
prognosis might be better
Maculopapular 
rash
up to 47% Mostly adults Nonspecific, drug 
hypersensitivity should be 
excluded
Acro-ischemic 
lesions
2.8–6% Thromboembolic, 
DIC
Red flag for severe course, 
mortality is high
SDRIFE-like Rare Exclude a drug reaction
Purpuric rash Unknown Underestimated in 
developing countries
Exclude other viral diseases, 
coinfections with dengue 
possible
EM Rare Unknown
KD Unknown Children Severe course, but often good 
prognosis
MIS-C Unknown Children Severe disease, ICU support
Mottling Rare Newborn Unknown
SS-like Rare Adults
Pustular 
eruptions
Rare Adults Probably 
hydroxychloroquine-induced
AGA ≤75% 
(males)
Adults, More severe 
course
Mediterranean Sea
AGA: Androgenetic alopecia, CE: Chilblain-like eruptions, EM: Erythema multiforme, DIC: Diffuse 
intravascular coagulation, KD: Kawasaki disease, MIS-C: Multisystemic Inflammatory Syndrome in Children, 
SS-like: Sweet syndrome-like eruptions, SDRIFE-like: Symmetrical flexural and intertriginous exanthema.
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Chilblain-like Acral Lesions
Clinics
Mostly asymmetrical distributed chilblain-
like violaceous, infiltrated acral areas of erythema, 
and/or edema with some vesicles or pustules 
(“pseudo-chilblain”) can be observed on hand and 
feet (Figure 1) [22]. Proximal nail fold capillaroscopy/
dermoscopy remains normal [23].
Figure 1: Asymmetric chilblain-like lesions. (a) Erythematous plaque 
on the antithenar. (b) Ill-defined infiltrations on two fingers. Nail fold 
capillaries are without abnormalities
ba
There is a number of case reports on chilblain-
like lesions mainly in children and adolescents. Pruritus 
and (mild) burning pain are two equally distributed major 
symptoms [24], [25], [26]. In a series of 63 patients, 
there was no significant gender difference. The median 
age was 14 years and feet alone were mostly affected 
(85.7%), followed by feet/hands together (7%) and 
hands alone (6%). Asymptomatic lesions were present 
in 25.4% of cases [27].
Frequency
The nationwide Spanish study reported 
chilblain-like lesions in 19% of cases [22]. In a 
retrospective observational nationwide study among 
French private practices, 277 patients were enrolled 
with a median age of 27 years. Chilblain-like lesions 
were the most frequent acral lesions (n=106/142, 
75%) [28].
In the rare cases with a lesional skin biopsy, 
vasculitis signs were noted in small to medium 
sized vessels with endothelial cell swelling and 
red blood cell extravasation. Fibrin thrombi was 
evident in superficial capillary vessels [29]. In an 
adult case, absence of significant papillary dermal 
edema was associated with a superficial and deep 
lymphoplasmacytic infiltrate, vacuolar interface 
dermatitis with some apoptotic keratinocytes and 
smudging of the basement membrane zone. The 
venules surrounded by the lymphoplasmacytic 
infiltrate had plump endothelial cells. Neither 
intraluminal fibrin thrombi nor venule wall fibrin 
deposits were detected. Direct immunofluorescence 
result was negative. Altogether these findings 
suggest a type I interferon response [30].
Significance
The percentage of patients with this type 
of cutaneous lesions tested positive for SARS-
CoV-2 is between 15% (prospective study) and 25% 
(retrospective study). This raises questions, if the 
chilblain-like lesions are markers of COVID-19 [31]. 
Some authors recommend SARS-CoV-2 testing in 
children and adolescents with chilblain-like lesions to 
support early detection of silent carriers [32].
Treatment
In uncomplicated cases topical mometasone 
furoate and heparin gel for a few days is 
recommended [33].
Vesicular Monomorphic Eruptions
Clinics
Vesicular monomorphic eruptions on the trunk 
or the extremities, with possible hemorrhagic content 
have been observed mostly in symptomatic COVID-19 
cases [22].
These lesions present initially as erythematous 
papules with a tendency to superficial vesiculation that 
eventually leads to crust formation. The presentation 
is varicella-like although most patients may be in good 
general health condition [34]. In a series of 22 patients 
from Northern Italy tested positive for SARS-Cov2, 
the median age was 60 years, and 72.7% of patients 
were male. The trunk as involved in all cases and the 
median time to remission was 8 days. Facial skin and 
mucosa were spared. Itch was noted in about 40% of 
patients [35].
Frequency
Vesicular monomorphic eruptions on the trunk 
or the extremities, with possible hemorrhagic content 
accounted for 9% of cases in the Spanish nationwide 
study [22]. In France, vesicular eruptions were observed 
in 41 outpatient cases (15%) [28].
Significance
The vesicular eruptions are considered probably 
COVID-19 specific, but vesicular drug-reactions and 
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other viral (co-)infections might contribute [36], [37]. 
Further studies are needed.
Treatment
These eruptions do not need any treatment, 
they can pass by itself. Wet dressing can be done to 
relieve the patient from itch. Topical antibacterial cream 
can be added if secondary impetiginization occurs.
Urticarial Rash
Clinics
Urticaria with wheals and flares is a non-
specific cutaneous symptom in COVID-19 patients 
(Figure 2). Here, urticarial lesions occur mostly on the 
trunk, rarely palmar. Pyrexia with urticaria may be more 
characteristic than urticaria alone [22].
Figure 2: Urticaria
Frequency
Urticaria was observed in 19% of Spanish 
COVID-19 patients and in in 1/14 in a French 
study [22], [26]. Among 140 hospitalized Chinese 
patients in Wuhan 1.4% self-reported urticarial [38]. 
A recent literature review reported urticaria in 9.7% of 
cases (7/72) [39].
Significance
In case of urticaria with eosinophils, theoretically 
a better outcome is possible [40]. Differential diagnoses 
include idiopathic urticaria, drug eruptions, and other 
viral infections with urticarial rash. If the patient is not 
taking medication and does not have idiopathic urticaria 
diagnosis, it is more likely to think of COVID-19 specific 
urticaria.
Treatment
Symptomatic treatment with oral antihistamines 
and topical corticosteroids is an option.
Maculopapular Rash
Clinics
Maculopapular rash is a non-specific 
cutaneous finding in COVID-19 patients (Figure 3). 
Lesions may show a possible perifollicular distribution. 
Variants were described as pityriasis rosea-like with 
a variable degree of purpuric areas or erythema 
elevatum diutinum-like. The rash lasts on average 
9 days. It is uncommon among children affected by 
COVID-19 [20].
Figure 3: Maculopapular rash. (a) Follicular type, (b) confluent 
lesions, (c) lichenoid follicular type
cba
Erythema multiforme-like eruptions have 
rarely been reported. They can spread to facial 
and palmoplantar skin and the average duration is 
double as long as the usual maculopapular rash with 
nearly 20 days. In a series of four adult patients, 
histologic examination revealed a normal basket-
weave stratum corneum, and mild-to-moderate 
epidermal spongiosis. Dermal vessels were dilated 
and filled with neutrophils with some extravasation 
of red blood cells, and lymphocytic perivascular and 
interstitial infiltrate. These patients needed systemic 
corticosteroids [41].
Pityriasis rosea-like eruptions are a rare pruritic 
cutaneous manifestation of COVID-19 [42].
Frequency
In the Spanish trial maculopapular rash was 
a common cutaneous finding observed in 47% of 
cases [22]. Face and palmoplantar skin is usually 
spared. Histologic and clinical presentation is not 
uniform. If needed, symptomatic topical treatment 
with corticosteroids and oral antihistamines can be 
used [20].
Significance
Maculopapular rash is a non-specific cutaneous 
finding in COVID-19. The most important differential 
diagnosis is drug-induced exanthema.
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Treatment
Symptomatic treatment with oral antihistamines 
and topical corticosteroids is an option.
Acro-ischemic Lesion (Livedo or 
Necrosis)
Clinics
Transient livedo reticularis-like lesions have 
occasionally been observed in symptomatic COVID-
19 patients. The livedoid changes may be unilateral 
in nature. They can eventually result in skin necrosis. 
The lesions are thought to be secondary to SARS-CoV-
2-induced thrombotic vasculopathy [22], [26]. Acro-
ischemia presenting with finger and toe cyanosis, skin 
bullae, and dry gangrene are a red-flag sign for severe 
illness (Figure 4).
Figure 4: Acro-ischemic ulcerations. (a) Transitory livedoid erythema. 
(b) Ulcerated papule. Disseminated ulcerated papules may be a sign 
of DIC. (c) Two neighboring ulcerations on the foot. (d) Ulcerated 
lesion on the heel
dc
ba
Frequency
The frequency of livedo and necrosis was 6% in 
Spain and 2.8% in a recent literature review [22], [39].
Significance
If livedoid and necrotic eruptions occur in 
COVID-19 patients, this could be a clue for systemic 
thrombotic vasculopathy. It will be particularly important 
to recognize the eruptions clinically, since they may 
have (strong negative) prognostic value in these 
patients.
It is important to separate acral lesions in 
the elderly from chilblain-like eruptions in youngsters 
since these could have a necrotic outcome [43]. Acro-
ischemia presentations are associated with severe 
COVID-19 disease and high mortality [44].
Treatment
Treatment is dependent on underlying 
pathology (acral ischemia, and disseminated 
intravascular coagulopathy [DIC]). In the initial phase 
of the SARS-CoV-2 infection, D-dimer and fibrinogen 
levels are increased, while prothrombin time, activated 
partial prothrombin time, and platelet counts are often 
normal. Diagnosis of DIC needs laboratory evaluation 
of soluble fibrin, protein C, and plasminogen activator 
inhibitor 1.
For hospitalized COVID-19 patients, 
thromboprophylaxis using low-molecular-weight 
heparin is recommended [45]. Recombinant human 
soluble thrombomodulin has proven clinically useful for 
treating DIC leading to a higher resolution rate after 7 
days of application [46]. Adjuvant plasmapheresis has 
been used occasionally in DIC [47].
Symmetrical Flexural and Intertriginous 
Exanthema
Clinics
Symmetrical flexural and intertriginous 
exanthema are a rare manifestation of COVID-19. 
It resembles clinically Symmetrical Drug-Related 
Intertriginous and Flexural Exanthema (SDRIFE).
Frequency
This symptom has been seen in single 
cases several days after the COVID-19 fever 
developed [48].
Significance
Drug-induced SDRIFE needs to be excluded 
before the diagnosis of COVID-19 SDRIFE can be 
made.
Treatment
Symmetrical flexural and intertriginous 
exanthema is temporary. In one case, it disappeared 
after 18 days without any specific treatment [48].
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Purpuric Rash
Clinics
Acute undifferentiated febrile illness is one of 
the initial presentations of COVID-19. Purpuric rash in 
COVID-19 may resemble other viral rashes like dengue 
fever [49], [50]. Very rare is Schamberg’s-like purpura 
in mild COVID-19 [51].
Frequency
The frequency is obviously dramatically 
underestimated in tropical countries [52].
Significance
In hotspots of arboviral diseases, these 
disorders need to be excluded [53]. On the other 
hand, SARS-CoV-2 and dengue fever have been 
reported as coinfections from various developing 
countries [54], [55], [41].
Treatment
Antipyretics and topical corticosteroids can be 
combined.
Erythema Multiforme-like Rash and 
Kawasaki-like Disease/MIS-C
Clinics
Four female hospitalized COVID-19 patients 
in Madrid, Spain, presented an erythema multiforme-
like rash. The mean age was 66.8 years. The mean 
time between onset of COVID-19 to the appearance 
of erythematous lesions was 19.5 days. Three patients 
developed the rash 4–7 days after clinical improvement 
with negative COVID-19 PCR test. These lesions 
developed from erythematous papules on the upper trunk 
that progressively turned into targetoid erythematous or 
violaceous patches with a dusky center, and a pseudo-
vesicle in the middle. They spread to the face and 
limbs within 1 week, but spared palms and soles. Oral 
mucosa was also involved with palatal macules and 
petechiae. Histological examination showed dilated 
dermal vessels filled with neutrophils, extravasation 
of red blood cells, and lymphocytic perivascular and 
interstitial infiltrate [41]. One case report from France 
described a 6-year-old boy with erythema multiforme-
like mucocutaneous lesions [56].
A prospective observational study from 
Paris, France, reported on 14 children with COVID-19 
and Kawasaki-like disease. Almost 60% originated 
from sub-Saharan Africa or Caribbean islands. All 
children had marked gastrointestinal symptoms 
and high levels of inflammatory markers. Eleven 
patients presented with Kawasaki disease (KD) shock 
syndrome requiring ICU support, and 12 suffered 
from myocarditis [57]. Kawasaki-like eruptions 
including generalized exanthema, cheilitis, stomatitis, 
and bilateral conjunctivitis, bilateral palmar edema, 
glossitis, and cervical lymphadenopathy had been 
reported in a 3-year-old boy. Cutaneous desquamation 
of the extremities was noted later on [56]. A 6-year-old 
girl with rT-PCR confirmed COVID-19 met criteria for 
incomplete KD, including fever for more than 7 days 
with conjunctivitis, rash, edema of the hands and feet, 
elevated CRP and erythrocyte sedimentation rate, 
hypoalbuminemia, anemia, and 2-D echocardiogram 
findings suggestive of myocarditis [58].
An important differential diagnosis of 
Kawasaki-like disease is MIS-C. MIS-C is characterized 
by (1) prominent cardiac dysfunction with troponin 
leak and extremely elevated brain natriuretic peptide, 
(2) frequent and often severe enteropathy, and (3) 
relative thrombocytopenia. In some patients, fever and 
gastrointestinal symptoms precede the classical KD 
features such as cutaneous rash, conjunctivitis, mucous 
membrane changes, and extremity edema [59].
Frequency
One series of 17 children and several 
case reports have been published so far 
[41], [56], [57], [60], [61].
Significance
Other viral (co-) infections such as parvovirus 
B19 and herpes simplex have to be excluded. 
Kawasaki-like disease often needs ICU support for 
affected children.
Treatment
If necessary, oral corticosteroids may be given 
temporary for erythema multiforme-like eruptions. 
In case of Kawasaki-like disease, intravenous 
immunoglobulins at 2 g/kg, systemic corticosteroids, 
and aspirin have been recommended [57], [61].
Other Cutaneous Findings
Mottling
A 15-day-old neonate of a SARS-CoV-2 
positive mother developed COVID-19 without cough. 
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The cutaneous findings were described as mottling. 
The newborn was isolated and subjected to supportive 
care. Antibiotic and antiviral treatment was initiated. 
The outcome was complete remission after 6 days [58].
Sweet syndrome-like eruptions
A 61-year-old woman without respiratory 
symptoms but fever, fatigue, arthralgia, and myalgia, 
was admitted to a hospital in Istanbul, Turkey. On 
examination, she presented numerous erythematous 
nodules on the cheeks, scalp, extremities, and the 
trunk. Minor aphthous ulcers were observed on the 
hard palate and buccal mucosa. Thoracic computerized 
tomography presented multifocal ground-glass opacities. 
The laboratory was remarkable for leukocytosis, 
neutrophilia, and mild lymphopenia, C-reactive protein 
was elevated with 78.2 (<5.0 mg/L). Although an initial 
SARS-CoV-2 rT-PCR was negative, a repeated test 
became positive. A skin biopsy from the elbow revealed 
a diffuse neutrophilic infiltration in the upper dermis and 
vascular proliferations with swollen endothelial cells and 
extravasated erythrocytes. In the lower dermis and at the 
periphery of the lobules of subcutaneous fat tissue, there 
were granulomas, composed of epithelioid histiocytes 
and multinuclear giant cells and other inflammatory cells. 
Clinical and histopathological features were considered 
as erythema nodosum-like Sweet syndrome [62]. 
Another case is shown in Figure 5.
Figure 5: Sweet-like plaques and pustules on the arms
Pustular rash
A 69-year-old woman from Madrid, Spain, with 
confirmed COVID-19 disease developed a pustular rash 
resembling acute exanthematous pustulosis 33 days 
after onset of COVID-19 symptoms. Histology revealed 
subcorneal pustulosis, spongiosis, papillary edema, 
and discrete neutrophilic inflammatory infiltrate [63]. 
Several other cases have been reported in adult COVID-
19 patients [64], [65]. Since these patients were treated 
with hydroxychloroquine, a delayed drug-reaction is 
possible [66]. A direct effect of SARS-CoV-2 remains 
unproven (Figure 6).
Figure 6: Acute exanthematic pustulosis due to hydroxychloroquine 
treatment of COVID-19
ba
AGA; Gabrin sign
AGA severity reflects the androgen activity over 
age. Among 175 confirmed and hospitalized COVID-19 
patients in Spain, 122 were males and 53 were females. 
AGA was present in 67% of the patients, 70 patients 
presented with clinically relevant AGA. The frequency 
of AGA was 79% in males and 42% in females. The 
prevalence of age matched males in a similar Caucasian 
population was estimated to be 31–53%, in females >70 
years and the prevalence reported was 38% [67]. This 
argues for a significant higher rate of AGA at least in 
COVID-19 positive males. Furthermore, it seems to be 
a marker for a more severe course of COVID-19 [68].
Dr. Gabrin was the first physician to die from 
COVID-19 in the US and suffering from AGA. Therefore, 
the eponym “Gabrin sign” has been proposed for AGA 
in COVID-19 patients [67].
Conclusions
During the COVID-19 pandemic dermatologists 
play an active role in patients’ triage, in early diagnosis 
of cutaneous signs, in the recognition of cutaneous red-
flags for an unfortunate course of the disease. Their active 
participation is necessary to record cutaneous findings, 
to confirm diagnoses and make the necessary differential 
diagnostic procedures [69]. The most important diseases 
to be considered are tropical and other viral disorders 
and drug hypersensitivities. However, we are still at the 
beginning and should be aware of unexpected findings.
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